期刊文献+

拓扑异构酶Ⅱα在乳腺癌中的研究现状 被引量:7

原文传递
导出
摘要 乳腺癌是女性最常见的恶性肿瘤之一,术后复发和转移率较高。乳腺癌化疗药物中含蒽环类药物阿霉素、表柔比星的AC(阿霉素、环磷酰胺)、CAF(环磷酰胺、阿霉素、5-FU)和CEF(环磷酰胺、表柔比星、5-FU)的联合化疗,已成为当今乳腺癌化疗的基础。拓扑异构酶(topoisomerase,Topo)Ⅱα是蒽环类药物的主要作用靶点,本文就TopoⅡα在乳腺癌发生、发展及治疗方面的研究进展作一综述。
出处 《中华病理学杂志》 CAS CSCD 北大核心 2008年第2期132-135,共4页 Chinese Journal of Pathology
基金 国家自然科学基金资助项目(30470667)
  • 相关文献

参考文献32

  • 1Linka RM, Porter AC, Volkov A, et al. C-Terminal regions of topoisomerase Ⅱ alpha and Ⅱ beta determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res, 2007,35 ( 11 ) :3810-3822.
  • 2Jarvinen TA, Liu ET. HER-2/neu and topoisomerase Ⅱ alpha in breast cancer. Breast Cancer Res Treat, 2003, 78(3):299-311.
  • 3Mano MS, Rosa DD, De Azambuja E, et al. The 17q12-q21 amplicon : Her2 and topoisomerase-Ⅱ alpha and their importance to the biology of solid tumours. Cancer Treat Rev, 2007, 33(1):64-77.
  • 4Fritz P, Cabrera CM, Dippon J, et al. c-erbB2 and topoisomerase Ⅱ alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res, 2005, 7(3):R374-R384.
  • 5Tinari N, Lattanzio R, Natoli C, et al. Changes of topoisomerase Ⅱ alpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res, 2006, 12(5) :1501-1506.
  • 6Jφrgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies-a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist, 2007, 12(4): 397-405.
  • 7Slamon D, Eierman W, Robert N, et al. Phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxoruhicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat, 2005, 94 ( Suppl 1 ) : S5.
  • 8Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase Ⅱ Inhibitor doxorubicin in breast cancer. Am J Pathol, 2000,156 ( 3 ) : 839-847.
  • 9Buzdar AU. Topoisomerase Ⅱ alpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol, 2006, 24(16) :2409-2411.
  • 10Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22 (47):7340-7358.

同被引文献63

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部